Loading company…
Valink Therapeutics develops bispecific antibody-drug conjugates for cancer treatment.
Founded in 2020 and based in Cambridge, Massachusetts, Valink Therapeutics develops bispecific antibody-drug conjugates for cancer. Its V-Gate approach is designed to target cancer cells based on molecular markers. The company raised USD 11.80 mn in funding led by Redalpine, with Hoxton Ventures and Oxford Sciences Enterprises among the investors.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in